A Cell & Gene production unit staffed by a highly trained team at Novartis will soon begin operating in Stein, Switzerland.
Novartis announced the company’s financial results for the second quarter and first half of 2019.
Novartis stands behind Zolgensma® for the treatment of children less than 2 years of age with spinal muscular atrophy.
How can digital help in the fight against malaria? Bertrand Bodson, our Chief Digital Officer, shares his own exper… https://t.co/6g6JFrFG8w
[email protected] of the Novartis Foundation and @SteveDavisPATH on how we can achieve #HealthForAll by making digital t… https://t.co/d4rTCYqTSI
#BreakingNews: Novartis receives FDA priority review for investigational biologic therapy for the prevention of… https://t.co/k5LrYrQhpK
This site is intended for a global audience.